Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Main objective : (1a) To demonstrate that at 1 month after the third dose of vaccine, both the modified process vaccine and COMVAX™ will induce adequate seroprotection rates (SPR, % of subjects with titer ≥ 10 mIU/mL) to hepatitis (1b) Conditional upon meeting (1a), to demonstrate that at 1 month after the third dose of vaccine, the modified process vaccine will induce similar (non-inferior) anti-HBs geometric mean titers (GMTs) as COMVAX™.
Critère d'inclusion
- Hepatitis B Infection